News
Celon Pharma S.A. Partners for the Commercialization of Reduzek (generics semaglutide) in the Gulf Cooperation Council (GCC) Countries
Celon Pharma S.A. has entered into a License and Supply Agreement with Pharmalink Drug Store L.L.C. for the commercialization of Celon Pharma’s generic semaglutide products in selected markets of the Gulf Cooperation Council (GCC) countries. The partnership represents another step in the Company’s strategy to build an international commercial presence for its GLP-1 analogue portfolio.Read more »
Current report no 9/2026 – Execution of an Agreement with Pharmalink for the Commercialization of Reduzek (semaglutide) in Selected Gulf Countries
Legal Basis: Article 17(1) of the MAR Regulation – Inside Information Report Content: The Management Board of Celon Pharma S.A. (the “Company”) hereby announces that on 8 June 2026 it entered into a License and Supply Agreement with Pharmalink Drug Store L.L.C. (“Pharmalink”) for the commercialization of Celon Pharma’s Reduzek (semaglutide products) in multi-dose pensRead more »
Current Report No. 8/2026 – Allocation of Series A Subscription Warrants to Eligible Participants under the Management Incentive Program
Legal basis: Article 17(1) of the MAR Regulation – Inside Information, 1:52 p.m. Report content: The Management Board of Celon Pharma S.A. (the “Company”) hereby announces that it has adopted a resolution regarding the allocation of a total of 55,000 Series A subscription warrants (the “Warrants”) under the Management Incentive Program for the year 2026.Read more »
Current Report No. 7/2026 – Notice of Convening the Annual General Meeting of Celon Pharma S.A. on June 24, 2026, Together with Draft Resolutions
Legal basis: Article 56(1)(2) of the Public Offering Act – Current and Periodic Information Report content: The Management Board of Celon Pharma S.A. (the “Company”), acting pursuant to Articles 395 §1, 399 §1, 402(1) and 402(2) of the Polish Commercial Companies Code (the “CCC”), hereby convenes the Annual General Meeting to be held on JuneRead more »
Representatives of the European Bank for Reconstruction and Development and Celon Pharma met to discuss the progress of the Reduzek project
This is strategic investment related to the development and production of GLP-1 semaglutide, used in the treatment of type II diabetes and obesity. During the meeting, the parties reviewed the current status of the project, the investment implementation schedule, and the financial cooperation concerning the construction and launch of the Celon Pharma Slovakia manufacturing facilityRead more »
Current Report No. 6/2026 – Four Celon Pharma S.A. Projects Selected for Funding under a Competition Announced by the Medical Research Agency
Legal basis: Article 17(1) of the MAR Regulation – Inside Information, 7:11 p.m. The Management Board of Celon Pharma S.A. (the “Company”) hereby announces that on May 5, 2026, it was informed that four of the Company’s applications for project funding (the “Projects”), submitted under the Medical Research Agency’s (Agencja Badań Medycznych, “ABM”) Competition forRead more »
Current report 5/2026 – Execution of Amendments to Agreements Concerning Cooperation with Tang Capital
Legal basis: Article 17(1) MAR – inside information, 17:04 Report content: With reference to current report No. 4/2024 dated 22 May 2024 regarding the execution by Celon Pharma S.A. (“Company”, “Celon”) and Tang Capital Management, LLC (“Tang Capital”) of agreements concerning cooperation aimed at establishing Novohale Therapeutics, LLC (“Novohale”) and the further development of theRead more »
Current Report No. 4/2026 – Execution of a Financing Agreement by the Issuer’s Subsidiary with the European Bank for Reconstruction and Development
Date of publication: March 9, 2026, 12:06 p.m. Legal basis: Article 17(1) of the MAR Regulation – Inside Information Report content: Further to Current Report No. 13/2025 dated August 4, 2025, regarding the agreement with the European Bank for Reconstruction and Development (“EBRD”) on the principal terms and conditions of financing to be granted toRead more »
Current Report No. 3/2026 – Resignation and Appointment of a Management Board Member of Celon Pharma S.A.
Legal basis: Article 56(1)(2) of the Public Offering Act – Current and Periodic Information Report content: The Management Board of Celon Pharma S.A. (the “Company”) hereby announces that on February 27, 2026, Mr. Bartosz Szałek submitted his resignation from the positions of Member of the Management Board and Chief Financial Officer of the Company, effectiveRead more »
Current Report No. 2/2026 – Summary of the FDA Type B Meeting for CPL’36 in the Treatment of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease (PD-LID)
Legal basis: Article 17 of the MAR Regulation – Inside Information, 5:13 p.m. The Management Board of Celon Pharma S.A. (the “Company”) hereby announces that on February 13, 2026, it completed its analysis of the written responses received from the U.S. Food and Drug Administration (“FDA”) to the questions submitted in the background package asRead more »